VKTX Stock Recent News

Viking Therapeutics (VKTX) shares rose more than 10% Wednesday after J.P. Morgan analysts initiated coverage of the company with an "overweight" rating and a price target of $80 per share, calling the company's oral weight-loss drug currently in clinical trials "underappreciated.

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc VKTX with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65.

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $54.78, signifying a +1.2% move from its prior day's close.

Viking Therapeutics is developing a weight management treatment candidate that is similar to Eli Lilly's Zepbound. Analysts' estimates for Viking Therapeutics point to huge gains for the stock over the next 12 months.

This stock already beat Nvidia's performance in the first half. This player operates in a market that could reach $100 billion by the end of the decade.

Viking Therapeutics, Inc. (VKTX) reachead $58.10 at the closing of the latest trading day, reflecting a -0.5% change compared to its last close.

VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.

Viking Therapeutics is developing medicines to fight obesity -- a hot area now. Its lead program appears to work better than blockbuster drugs made by others.

Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations. Despite competition from Eli Lilly and Novo Nordisk, VK2735's unique oral formulation could position Viking as a strong contender in the obesity drug market. VKTX's financial stability, with $942 million in cash and equivalents, supports its ongoing and future clinical trials, making it a viable long-term investment.

SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will be the featured speaker in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference.